|
Name |
Palmarumycin C16
|
| Molecular Formula | C20H18O7 | |
| IUPAC Name* |
(1'R,2'R,3'S,5'S,7'R,11'R)-spiro[2,4-dioxatricyclo[7.3.1.05,13]trideca-1(12),5,7,9(13),10-pentaene-3,6'-4,12-dioxatetracyclo[5.4.1.01,7.03,5]dodecane]-2',8',11'-triol
|
|
| SMILES |
C1CC([C@]23[C@]([C@@H]1O)(O2)[C@@H]([C@H]4[C@@H](C35OC6=CC=CC7=C6C(=CC=C7)O5)O4)O)O
|
|
| InChI |
InChI=1S/C20H18O7/c21-12-7-8-13(22)19-18(12,27-19)16(23)15-17(24-15)20(19)25-10-5-1-3-9-4-2-6-11(26-20)14(9)10/h1-6,12-13,15-17,21-23H,7-8H2/t12-,13?,15+,16-,17+,18-,19-/m1/s1
|
|
| InChIKey |
QCIVQEKYSGBTOX-LYYLEWAKSA-N
|
|
| Synonyms |
Palmarumycin C16
|
|
| CAS | NA | |
| PubChem CID | 10248564 | |
| ChEMBL ID | NA |
Chemical Classification: |
|
|
|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
|---|---|---|---|---|---|---|---|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
| Molecular Weight: | 370.4 | ALogp: | 0.4 |
| HBD: | 3 | HBA: | 7 |
| Rotatable Bonds: | 0 | Lipinski's rule of five: | Accepted |
| Polar Surface Area: | 104.0 | Aromatic Rings: | 7 |
| Heavy Atoms: | 27 | QED Weighted: | 0.591 |
| Caco-2 Permeability: | -5.598 | MDCK Permeability: | 0.00003210 |
| Pgp-inhibitor: | 0.008 | Pgp-substrate: | 0.984 |
| Human Intestinal Absorption (HIA): | 0.341 | 20% Bioavailability (F20%): | 0.141 |
| 30% Bioavailability (F30%): | 0.814 |
| Blood-Brain-Barrier Penetration (BBB): | 0.927 | Plasma Protein Binding (PPB): | 91.17% |
| Volume Distribution (VD): | 0.58 | Fu: | 3.11% |
| CYP1A2-inhibitor: | 0.052 | CYP1A2-substrate: | 0.156 |
| CYP2C19-inhibitor: | 0.035 | CYP2C19-substrate: | 0.367 |
| CYP2C9-inhibitor: | 0.043 | CYP2C9-substrate: | 0.06 |
| CYP2D6-inhibitor: | 0.007 | CYP2D6-substrate: | 0.365 |
| CYP3A4-inhibitor: | 0.052 | CYP3A4-substrate: | 0.196 |
| Clearance (CL): | 10.979 | Half-life (T1/2): | 0.644 |
| hERG Blockers: | 0.086 | Human Hepatotoxicity (H-HT): | 0.996 |
| Drug-inuced Liver Injury (DILI): | 0.963 | AMES Toxicity: | 0.533 |
| Rat Oral Acute Toxicity: | 0.774 | Maximum Recommended Daily Dose: | 0.891 |
| Skin Sensitization: | 0.637 | Carcinogencity: | 0.552 |
| Eye Corrosion: | 0.003 | Eye Irritation: | 0.019 |
| Respiratory Toxicity: | 0.966 |
| Similar NPs | Similar Drugs | ||||||
|---|---|---|---|---|---|---|---|
| NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
| ENC003197 | ![]() |
0.784 | D06ALD | ![]() |
0.230 | ||
| ENC002185 | ![]() |
0.733 | D0Q3VE | ![]() |
0.227 | ||
| ENC002330 | ![]() |
0.681 | D00JRA | ![]() |
0.214 | ||
| ENC003239 | ![]() |
0.681 | D0Z1FX | ![]() |
0.212 | ||
| ENC003238 | ![]() |
0.626 | D0O6IZ | ![]() |
0.212 | ||
| ENC001999 | ![]() |
0.625 | D01TNW | ![]() |
0.209 | ||
| ENC003195 | ![]() |
0.602 | D06BQU | ![]() |
0.209 | ||
| ENC003196 | ![]() |
0.570 | D0W6KM | ![]() |
0.200 | ||
| ENC003194 | ![]() |
0.524 | D08CCE | ![]() |
0.200 | ||
| ENC003198 | ![]() |
0.486 | D08DFX | ![]() |
0.196 | ||